

## **Conundrum of re-positives COVID-19 cases: A Systematic review of Case reports and Case series**

Authors Information:

Dr Arun Kumar Yadav, MD(Community Medicine), DNB, PhD. Associate Professor, AFMC, [arunyadavpsm@gmail.com](mailto:arunyadavpsm@gmail.com)

Dr Subhadeep Ghosh, MD(Community Medicine), Professor, ACMS, [armdoc72@yahoo.co.in](mailto:armdoc72@yahoo.co.in)

Dr Sudhir Dubey, MD (Microbiology), Associate Professor

### **Abstract**

#### **Introduction**

There have been case reports and case series published for RT PCR positive COVID - 19 cases that became RT PCR negative but subsequently became RT PCR positive after a symptom free interval following a negative RT PCR test. These cases may include re-positive, reactivated and re-infection cases. Hence, the systematic review to summarize and synthesize evidence from all available case series and case reports published was undertaken.

#### **Methodology**

The systematic review of case series and case reports was registered with Prospero with registration number CRD42020210446. PRISMA guidelines were followed for conducting the systematic review. Studies published in English language only were considered for the Systematic Review. Inclusion criteria for studies included case reports and case series which have documented cases of positive RT-PCR after a period of improvement or negative RT PCR. Reviews, opinions and animal studies were excluded. Case reports which described clinical presentation or manifestations of COVID-19 cases were also excluded from the studies. Methodological quality was assessed using modified Murad scale.

## Results

A total of 30 case reports/case series were included in the study, wherein a total of 219 cases were included. In re-positive cases, the age range varied from 10 months to 91 years. The pooled proportion using random effects was 12% with 95% CI from 09% to 15%. Among the re-positives, a total of 57 cases (26%) of the cases had co-morbidities. A total of 51 (23.3%) and 17 (7.8%) re-positive cases had been treated with antivirals and corticosteroids respectively. Among the symptomatic cases, the disease severity was lesser as compared to the initial episode of illness. Only a few studies have confirmed the presence of antibodies after the first episode. The few studies that had done contact tracing of re-positives did not find any positive cases among those in contact with re-positives.

## Conclusion

This systematic review presents the review of all the case reports and case series on recurrence of COVID 19 disease. Although limited evidence has been generated due to paucity of such studies and shortcomings in the study designs of case reports and case-series, nonetheless, the evidence generated can still be used in making clinical decisions and framing policy guidelines

## Full article

Reactivated/relapse/re-positive/re-infection COVID 19 cases: A Systematic review of Case reports and Case series

### Introduction

Clusters of cases of atypical pneumonia were reported from Wuhan city, China in Dec 2019 in hubei province (1). The disease was later renamed as COVID-19 and the agent was later identified as Severe Acute Respiratory Syndrome Corona Virus -2(2). WHO

has declared it as public health emergency of International concern (PHEIC) on 30 Jan 20 and subsequently as a pandemic on 11 Mar 20(3).

As on 16 September 2020 29,444,198 COVID cases and 9,31,321 deaths have been reported globally (4). More than nine months into the pandemic, steady accumulation of scientific data and evidence in the context of disease dynamics, transmission, pathophysiology, diagnostic and treatment modalities, a large number of existing knowledge gaps have gradually been filled; however certain aspects of the disease pertaining to immune response to the disease (Humoral versus Cellular Immunity, persistence of acquired immunity and natural immunity to the disease) are still in a nascent stage of conception. These issues assume greater importance with reports of re-activation/ relapse of the disease creating sensational headlines and the imminent development and marketing of a plethora of vaccines on the anvil.

There have been various case reports and case series published for RT PCR positive COVID -19 cases who have become RT PCR negative and again become RT PCR positive after symptom free period or RT PCR negative test. These cases may include, re-positive, reactivated and reinfection cases. It is not known whether these cases share common characteristics or may share common characteristics which may help in identification prior to their discharge. The systematic review of the case reports and case series of the re-positive may help in better understanding of the natural history of the disease. Hence, systematic review to summarize and synthesize evidence from all the case series and case reports published was undertaken.

## Methodology

The systematic review of case series and case reports was registered with the Prospero with registration number CRD42020210446. PRISMA guidelines were followed for conducting the systematic review. A detailed literature search was done till 12 Sep 2020 for studies having reported cases of COVID-19 after a symptom-free interval. The databases that were searched included Medline through Pubmed, and Cochrane databases. The key term used were COVID-19, Severe Acute Respiratory Syndrome Corona Virus, Relapse, Reactivation and Re-infection. The detailed search for Pubmed is given in supplementary table 1. Hand searches of the references of articles was also

done. Observational studies including Case Reports and Case Series which have reported COVID -19 cases after a symptom free interval were taken into the systematic review. Studies published in English language only were considered for the Systematic Review. Inclusion criteria for studies includes case reports and case series who have documented cases of positive RT-PCR after period of improvement or negative RT PCR. Review, opinions and animal studies were excluded. Case reports which described clinical presentation or manifestations of COVID-19 cases were also excluded from the studies.

A data extraction form was synthesized and data was extracted by two authors independently. The data items consisted of age and sex of the patients, clinical co-morbidities, date of initial positive PCR test, date of negative PCR test based on which the patient was declared as cured and date of positive PCR test in recovered individuals who reported with fresh onset of symptoms suggestive of COVID-19 infection after a disease free interval. Data on serology (If performed) and clinical outcome of patients was also collated.

Methodological quality will be assessed using the existing guidelines (5). The narrative synthesis of the results would be done. The meta-analysis technique for pooling of results would be used wherever possible.

#### Results:

The selection of the study is shown as PRISMA Chart in Figure 1. A total of 29 case reports/case series were included in the study. A total of 219 cases from 30 studies were included in the study. The details and characteristics of the patients in the case series and case reports are shown in table 1(6–25,25–34).

A total of eight studies gives the proportion of cases who are positive after the follow-up period which ranges from one week to seven weeks. A total of eight studies have mentioned proportion of cases who became repositive after negative RT PCR test. The summary of proportions and their pooled ratio is given in figure 2. The pooled proportion using random effects was 12% with 95% CI from 09% to 15%. All studies

had follow up period of in the range 4-17 days except Jianghong et al which had followup time of 14-46 days.

The age range of the recurrence cases varies from 10 months to 91 years of age. The pooled mean age of 195 cases was  $44.3 \pm 19.2$  years. Zhao et al studied recurrence in children and wu et al data for combining the age was not mentioned(21,23). A total of 111 out of 209 were females. Sex was not mentioned for 10 cases.

The COVID 19 testing among discharged patients has been done from sputum ( lower respiratory tract), nasopharyngeal and anal swab the details are shown in table 1.

A total of 136 (62.1;95% CI: 55.3 – 68.5)COVID Cases were symptomatic, However, the status was not known for 70 (32%) COVID cases at initial presentation. Only 12 cases (5.5 : 95% CI ; 2.8 – 9,4) were of severe cases as reported in the studies. Majority of the cases (197, 89.9%) had mild-moderate presentation While the presentation was not known for 10 COVID cases. A total of 57 cases (26%) of the repositives cases have Co-morbidities. A total of 51 and 17 COVID cases had taken antivirals and corticosteroids respectively. A total of 64 (29.2%) reported COVID cases were symptomatic in second episodes, 150 (68.5%) were asymptomatic and the status of five was unknown. The range of days for positivity varied from 03 days to 101 days after discharge.

Only a few studies confirmed the antibody presence after first episode (table 1). However even after development of antibody studies have reported re-positivity. Only a few studies have looked into genetic analysis of the SARS COV2 to confirm the reinfection.

Few studies had done contact tracing of repositives, however to date did not find any positive cases in contact with repositives.

The mortality has been reported in seven repositives cases. The age range of these cases varies from 73-91 years. All of them had multiple co-morbidities.

A total of only 63 reported cases were symptomatic after the first episode, however, the majority of them were less severe than the first episode of COVID 19 cases. Only few studies have shown antibody formation after first episode.

The quality of studies assessed by using the modified Murad et al scale is shown in figure 3. In most of the methods selection methods are not clear and also there were no precautions taken for ruling out false positive or rule out the pathogen.

Korea Centers for Disease Control and Prevention reported 141 cases positive by RT PCR after they recovered from COVID-19(35). However, the probable reason given was relapse or inconsistent tests. The details were not available on the site.

Risk of bias. Though there are no set guidelines for the estimation of the risk of bias, the author feels that initial PCR positive, subsequent PCR negative, serological testing and PCR positive after symptom-free period are essential for draw conclusion about relapse or reinfection. Only case reports by Lafai et al and Enrico et al have reported negative PCR(7,8). Case reports by Batissee et al and Ravioli et al did not mention a negative PCR test after first COVID infection(6,10). Loncosole et al provided all the requisite information(11)

## Discussion

### Definition of relapse

The systematic review was done of all case reports and case series to identify common characteristics and evidence available for repositives of the cases. Though in literature search we found evidence of repositives of COVID 19 cases after symptoms free and negative RT PCR test, yet it is difficult to ascertain whether it was due to continuous shedding of the virus, relapse, or reinfection of the virus. Only six studies are there which have done the genetic analysis of the COVID 19 virus and found different genetic disease among those who have recovered from the COVID -19.

The recurrence has been observed across all ages from 10 months to 91 years of age. The mortality is seen in older cases with multiple co-morbidities in consonance with the

primary infection. Immunity of the individual may also influence recurrences. Hence immunosenescent of the old age as well immunosuppressants drugs may affect the recurrence. However, majority of the COVID 19 repositives cases were not given corticosteroids. Many repositives cases were also given antiviral drug. However there is a limitation of making inference from the systematic review as no valid control group were not present and secondly the denominator in case reports or case series is difficult to ascertain. The effect of other immunomodulator and antiviral drug on recurrence may be studied in well designed study.

The pooled proportion of studies that have given the proportion of COVID 19 repositives was done. Around 12% of discharged COVID 19 cases after comes out positive. The reasons may be related to Intermittent shedding of virus, the persistence of the virus, testing technique including sampling, or host characteristics. The persistence of virus in body is known phenomenon for SARS-associated Coronavirus(36). As of now there was no evidence of secondary cases from these repositives, however, the possibility of spread of infection does exist. This underlines the importance of surveillance of discharge cases of COVID 19.

Different site for sample may also have some effect as in many cases even if the sample from nasopharyngeal are negative, the samples from sputum ( lower respiratory tract ) and anal swab have been positive. There is an evidence that virus may be shed longer from extraphranging site. There are reports that of virus shedding from asymptomatic patients may continue from extrapulmonary sites in various bodily fluids (Saliva, tears, feaces, throat, or nasal discharge) for longer duration of time(37,38). Its role in re-infection is still not known. However there are few studies which suggests no role of shedding of virus on reinfection(39)

Yuan et al noted no difference between among repositives and negatives for antibody formation and also reported that asymptomatic cases may be repositives. The animal studies however have shown the prevention of reinfection with antibody formation(40) The role of antibody in virus shedding and reinfection may needs to be elucidated in further studies. Re-infection may lead to the selection of escape mutants and subsequent dissemination to the population.

Antibody dependent enhancement is a known phenomenon in viral disease, responsible for increased severity of subsequent infections, However, in this systematic review we found that majority of re-positives cases were milder than first infection. This may be due to reasons that most of the cases are not reinfection but persistence of same infection or interaction between virus-virus. A modelling for reinfection has concluded that the rate of reinfection by the recovered population will decline to zero overtime as the virus is cleared clinically from the system of the recovered class(41)

This systematic review presents the review of all the case reports and case series on recurrence of the diseases. The evidence generated may not be of high level but can still be used in making clinical decision and policy making. Clinician may suspect the COVID cases among recovered cases in which all other diagnosis has been ruled out and policy makers and public health specialist may need to modify the policy as per newer evidence. The infectiousness of these recurrence cases may need to be further explored as this will have major implication on public health policy.

Since these patients of recurrence may represent special subset of COVID cases, the findings may not be generalizable to all COVID cases. More research is needed to delineate the factors responsible for recurrence in cases. As the pandemic progress the evidence would need further revision. Nevertheless, there a strong case for proper documentation of all the cases to further refute or confirm the findings.

## References

1. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med [Internet]. 2020 Feb 20 [cited 2020 Aug 17];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033263/>
2. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. [cited 2020 Aug 17]. Available from: <https://www.who.int/emergencies/diseases/novel->



coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

3. Coronavirus (COVID-19) events as they happen [Internet]. [cited 2020 Aug 17]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>
4. Coronavirus disease (COVID-19) – World Health Organization [Internet]. [cited 2020 Aug 17]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
5. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. *BMJ Evidence-Based Medicine*. 2018 Apr 1;23(2):60–3.
6. Batische D, Benech N, Botelho-Nevers E, Bouillier K, Collarino R, Conrad A, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? *J Infect* [Internet]. 2020 Jun 30 [cited 2020 Aug 13]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326402/>
7. Lafaie L, Célarier T, Goethals L, Pozzetto B, Sylvain G, Ojardias E, et al. Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases. *Journal of the American Geriatrics Society* [Internet]. [cited 2020 Aug 13];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.16728>
8. Bentivegna E, Sentimentale A, Luciani M, Speranza ML, Guerritore L, Martelletti P. New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. *Journal of Medical Virology* [Internet]. [cited 2020 Aug 13];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26160>
9. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J Infect*. 2020;80(5):e14–7.
10. Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: A report of two cases. *J Infect*. 2020 Aug;81(2):e72–3.
11. Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al. Recurrence of COVID-19 after recovery: a case report from Italy. *Infection*. 2020 May 16;
12. Jiang M, Li Y, Han M, Wang Z, Zhang Y, Du X. Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19). *J Infect*. 2020 Jul;81(1):147–78.
13. Chang S-C, Wang J-T, Huang L-M, Chen Y-C, Fang C-T, Sheng W-H, et al. Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients. *Clin Diagn Lab Immunol*. 2005 Dec;12(12):1455–7.

14. Yoo SY, Lee Y, Lee GH, Kim DH. Reactivation of SARS-CoV-2 after recovery. *Pediatrics International*. 2020;62(7):879–81.
15. Liu F, Cai Z, Huang J, Yu W, Niu H, Zhang Y, et al. Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up. *Pathog Dis* [Internet]. 2020 Jun 27 [cited 2020 Aug 28]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337794/>
16. Yuan B, Liu H-Q, Yang Z-R, Chen Y-X, Liu Z-Y, Zhang K, et al. Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. *Scientific Reports* [Internet]. 2020 Dec [cited 2020 Sep 5];10(1). Available from: <http://www.nature.com/articles/s41598-020-68782-w>
17. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. *JAMA*. 2020 Apr 21;323(15):1502–3.
18. Cao H, Ruan L, Liu J, Liao W. The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge. *J Med Virol* [Internet]. 2020 Jun 2 [cited 2020 Sep 7]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272974/>
19. Deng W, Guang T, Yang M, Li J, Jiang D, Li C, et al. Positive results for patients with COVID-19 discharged from hospital in Chongqing, China. *BMC Infectious Diseases* [Internet]. 2020 Dec [cited 2020 Sep 7];20(1). Available from: <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05151-y>
20. Peng J, Wang M, Zhang G, Lu E. Seven discharged patients turning positive again for SARS-CoV-2 on quantitative RT-PCR. *American Journal of Infection Control*. 2020 Jun 1;48(6):725–6.
21. Wu J, Liu X, Liu J, Liao H, Long S, Zhou N, et al. Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China. *JAMA Netw Open*. 2020 May 1;3(5):e209759–e209759.
22. Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19. *Journal of Medical Virology* [Internet]. [cited 2020 Aug 13];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26353>
23. Zhao W, Wang Y, Tang Y, Zhao W, Fan Y, Liu G, et al. Characteristics of Children With Reactivation of SARS-CoV-2 Infection After Hospital Discharge. *Clin Pediatr (Phila)*. 2020 Sep 1;59(9–10):929–32.
24. Li J, Long X, Fang X, Zhang Q, Hu S, Lin Z, et al. SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report. *Clinical Microbiology and Infection*. 2020 Aug 1;26(8):1115–7.

25. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. *International Journal of Infectious Diseases*. 2020 Apr 1;93:297–9.
26. Hu R, Jiang Z, Gao H, Huang D, Jiang D, Chen F, et al. Recurrent Positive Reverse Transcriptase–Polymerase Chain Reaction Results for Coronavirus Disease 2019 in Patients Discharged From a Hospital in China. *JAMA Netw Open*. 2020 May 1;3(5):e2010475–e2010475.
27. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. *medRxiv*. 2020 Mar 30;2020.03.26.20044222.
28. Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. A case report of possible novel coronavirus 2019 reinfection. *American Journal of Emergency Medicine* [Internet]. 2020 Jan 1 [cited 2020 Aug 13]; Available from: <https://covid19.elsevierpure.com/ri/publications/a-case-report-of-possible-novel-coronavirus-2019-reinfection>
29. Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19 | Elsevier Enhanced Reader [Internet]. [cited 2020 Sep 7]. Available from: <https://reader.elsevier.com/reader/sd/pii/S1477893920300879?token=8E8AB4EE43A1E6B85A023FA137DA6C98C2B181CF501166FF1985F274B2F80305ED97584903CA626907762F333E0067EA>
30. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis*. 2020 Aug 25;
31. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *The Lancet Infectious Diseases* [Internet]. 2020 Oct 12 [cited 2020 Oct 13];0(0). Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30764-7/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30764-7/abstract)
32. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. *Clin Infect Dis*. 2020 Sep 5;
33. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et al. COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America. [Internet]. Rochester, NY: Social Science Research Network; 2020 Sep [cited 2020 Oct 13]. Report No.: ID 3686174. Available from: <https://papers.ssrn.com/abstract=3686174>

34. Gupta V, Bhojar RC, Jain A, Srivastava S, Upadhyay R, Imran M, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. *Clin Infect Dis* [Internet]. 2020 Sep 23 [cited 2020 Oct 14]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543380/>
35. www.ETHealthworld.com. Why are some S.Koreans who recovered from the coronavirus testing positive again? - ET HealthWorld [Internet]. ETHealthworld.com. [cited 2020 Aug 15]. Available from: <https://health.economictimes.indiatimes.com/news/industry/why-are-some-s-koreans-who-recovered-from-the-coronavirus-testing-positive-again-/75178047>
36. Isakbaeva ET, Khetsuriani N, Beard RS, Peck A, Erdman D, Monroe SS, et al. SARS-associated Coronavirus Transmission, United States. *Emerg Infect Dis*. 2004 Feb;10(2):225–31.
37. Kalkeri R, Goebel S, Sharma GD. SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs. *The American Journal of Tropical Medicine and Hygiene*. 2020 Jul 8;103(1):18–21.
38. Du W, Yu J, Liu X, Chen H, Lin L, Li Q. Persistence of SARS-CoV-2 virus RNA in feces: A case series of children. *Journal of Infection and Public Health*. 2020 Jul 1;13(7):926–31.
39. No infectious risk of COVID-19 patients with long-term fecal 2019-nCoV nucleic acid positive [Internet]. *European Review*. 2020 [cited 2020 Aug 15]. Available from: <https://www.europeanreview.org/article/21370>
40. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv*. 2020 Mar 14;2020.03.13.990226.
41. Okhuese AV. Estimation of the Probability of Reinfection With COVID-19 by the Susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible Model. *JMIR Public Health and Surveillance* [Internet]. 2020 Jun [cited 2020 Aug 24];6(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223428/>

**Fig: 1 Prisma Chart for the inclusion of studies in the systematic review.**




Figure 2: Pooled proportions from studies.





Figure 3: Quality of study as assessed using modified



**Table 1 : Characteristic of studies**

S no	Study	Age and sex	Country	Sympt	Co-morbidity	Severity	Date of First COVID 19 (PCR)	Test Done	Serological test done after first episode	RT PCR negative after first episode	Symptomatic again after period of weeks	Date of Second COVID 19	Test done	Outcome
1	Batiss e et al 1 2 3 4 5 6 7 8 9 10 11	19, F 32, F 33, F 43, M 85, M 54, M 91, F 55, M 72, M 73, M 84, F	France	Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	7 Comorbidity: 4 No comorbidity	11- mild	D2 D18 D3 D1 D16 D38, 44 D3 D6 D7 D6 D11	RT PCR	Avl for 9 patients 5 were positive, one slightly positive and three negatives (recd chemotherapy and rituximab)	NM	Yes Yes Yes Yes Yes Yes Yes Yes Yes	D29, D36, 55 D28 D38 D46 D45 D26 D31 D23, 32, 36 D35 D50	RT PCR	3 Dead and 8 recovered
2	Lafai et al 1 2 3	84, F 90, F 84, F	France	Yes Yes Yes	Yes Yes Yes	Sev -3	26 Mar 05 Apr 15 Apr	PCR PCR PCR PCR* (neg)	Yes** No Yes**	No No Yes	Yes Yes Yes	26 days 15 days 11 days	RT PCR RT PCR RT PCR	Deat h Deat h Deat h
3	Enrico et al	69, F	Italy	Yes	Yes	Mild	24 Mar	PCR	Yes IgG	Yes (tw)	Yes	32 days	RT PCR	Disc harg



									Positive	o)				ed
4	Ye et al 1 2 3 4 5	30, M 42, M 32, F 27, F 31, F	China	Yes Yes Yes Yes No Yes	No No No No	Mild Mild Mild Mild	NM	NM	NM	Yes Yes Yes Yes	NM	NG (4-17 days after negative test)	RT PCR RT PCR RT PCR RT PCR RT PCR RT PCR	Stable Stable Stable Stable Stable Stable
5	Ravioli et al 1 2	81, F 77, F	Switzerland	Yes Yes	Yes Yes	Moderate	09 Mar 23 Mar	PCR PCR	NM NM	Yes Yes	Yes Yes	21 14	RT PCR RT PCR RT PCR	Died Stable
6	Loconsole et al	48, M	Italy	Yes	No	Severe	17 Mar	PCR	Yes	Yes	Yes	30	RT PCR	Stable
7	Jiang et al(6) 1 2 3 4 5 6	35 F 56 F F F F	China	Yes Yes Yes Yes Yes Yes Yes	No Yes No No Yes No	Mild	30 Jan 30 Jan 03 Feb 03 Feb 05 Feb 06 Feb	PCR PCR PCR PCR PCR PCR PCR	No No No No	Yes Yes Yes Yes	Yes No Yes No No	9 days 14 days 8 days 7 days 9 days 5 days	PCR PCR PCR PCR	Re-hosp Stable Stable Stable Stable Alive Alive
8	Chang et al(7) 1 2 3 4 5 6 7	14M 13M 10 (months) F 35M 35M 33M 26M	China	No No Yes Yes No No Yes	No No No No No No	Mild-6 Moderate-1	01 Feb 01 Feb 05 Feb 02 Feb 31 Jan 27 Jan 26 Jan	PCR PCR PCR PCR PCR PCR PCR	No No No No No	Yes Yes Yes Yes yes	No No No No No	7 11 9 9 8 5 11	4RS 2PCR 1PCR and 1 Rs	Alive Alive Alive Alive Alive Alive
9	Yoo et al	8M	Korea	Yes	No	Mild	03 Mar	PCR	No	Yes	Yes	14	PCR	Alive
10	Liu et al	35 M	China	yes	No	Mild	30 Jan	PCR	Yes	Yes	Yes	15	PCR	Alive
11	Yuan et al (20/18)	38M	China			Mild to	NM	PC	14 were tested	Yes	20 -No	13-	14	Stable

	2) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	53M 40F 61F 64F 53F 33F 1F 34F 43M 34F 38M 50F 50F 5F 55F 72F 54M 8M 12M	a	19- Ye s 1 - No	6 peopl e had comm oditie s	mod erat e		R	and all of them have antibo dies			retes ted at 07 days 7 retes ted 14 days	nasoph arynge al and 7 anal swabs	e
1 2	Lan et al 1 2 3 4	30- 36, 2 M	Chin a	3- symp 1- asym p	NM	Mild to mod erat e	NM	PC R	NM	Yes	aymp	5-13 days after disc hage	PCR	Alive
1 3	Cao et al 1 2 3 4 5 6 7 8	54F 72F 60F 65F 58M 64M 36F 26M	Chin a	Sym No No No Hypot h No No No No	No No No Hypot h No No No No	Sev ere Mod erat e Mod erat e Mod erat e Mod erat e Sev ere Mod erat e Mod erat e	NM	PC R	NM	Yes Yes Yes Yes Yes Yes Yes	Asym Asym Asym Asym Asym Asym Asym	12 14 09 12 16 29 06 06	PCR	Alive
1 4	Deng et al 576 (conta ct were negativ e)	61/5 76 (10. 6%) Age - 54.8 year s, 36 F	Chin a	NM	24 (39.3 %)	Sev ere 3 (4.9 %)	NM	PC R	Not done	Yes	38 asym (Mild status)	0 (7- 13)	36PCR : 17 stools; 8 sputum	Alive

		(23 were adm antiviral)												
15	Peng et al 1 2 3 4 5 6 7	67M - M - F - M 38F 29M 21F	China	Sym Sym Sym Sym Sym Sym Sym	NM NM NM NM NM NM	Mild Mild Mild Mild Mild	24 Jan 24 Jan 27 Jan 28 Jan 24 Jan 29 Jan 31 Jan	PCR NM PCR R NM PCR R R R	NM NM NM NM NM	Yes Yes Yes Yes Yes	Asym Asym Asym Asym Asym	4 6 3 7 6 6 5	PCR PCR PCR AS AS PCR	Alive Alive Alive Alive Alive Alive
16	Wu et al  No contacts 1 2 3 4 5 6 7 8 9 10	>70 >70 NM NM NM NM NM NM NM	China	NM NM NM NM NM NM NM NM NM	Yes Yes NM NM NM NM NM NM	NM NM NM NM NM NM NM	01Feb 02Feb b' 02Feb b 23Jan 27Jan n 30Jan 29Jan 28Jan 07Feb 07Feb	NM NM NM NM NM NM NM NM NM NM	NM NM NM NM NM NM NM NM NM	NM NM NM NM NM NM NM NM NM	Symp Symp Asym p Asym p Asym p Asym p Asym p Asym p	3 5 6 25 16 9 22 23 11 07	P PA A P P A A A A	Alive Alive Alive Alive Alive Alive Alive Alive
17	Zhou et al(11) (antiviral)	40M	China	Sym	B cell deficiency	Severe	23Jan	PCR	YES 9 Day 31 and day 33) lower level of antibody	YES	YES 5	5 days after discharge	PCR	Alive
18	Zhao et al (12) (7/14) Second reactivation in 2	5.7 (2.9-7.3)r 4 F	China	5 symp to and 2 asymp	No Co-morbidity	Mild	NM	PCR	NM	Yes	6 asymp 1 symp	14 days from discharge (7-17)	PCR	Alive
1	Li et al	50M	China	Sym	Yes	Mild	D13	PCR	Yes	yes	Aymp	14	PCR	Alive

9	(13)		a	m				R	on D 40. IgM and IgG positiv e						
20	Chen et al (14) 1 2 3 4	29M 49F 12F 38M	China	Symp Symp Asymp symp	NK NK NK Nk	Mild Mild Mild mild	01 Feb 02 Feb 05 Feb 30 Jan	PCR	NM NM NM NM	Yes Yes Yes Yes	Asymp p Asym Asym Asym	3 3 3 3	PCR	Alive	
21	Hu et al (11/69) 33years (2-78 years) (15)	11 median age 27, range 4-58 years 4 F	China	9 – mod 1- mil d 1- criti cal	3 patients	Mild 1 Mod 9 Severe 1	NM	PCR	NM	Yes	Asymp p	14 (9-17)	PCR	Alive	
22	Jianghong An et al (n=262) Mild - 30 Mod 212 Severe 20	Median age 20 (5-64) 7 F 38 (2-60) 15 F	China	Yes	1/11 1/27	Mild -11 Moderate 27	Patient were discharged, Jan23 to Feb 25 (14 days)	RT PCR, Anal swab	Yes no difference between the two groups	Yes	No	Weekly after discharge	RT PCR	Recovered	
23	Chen et al	46 F	China	Fever	no	Mild	24 Jan	RT PCR	No	Yes	No	03 days after last negative test	RT PCR	Recovered	
24	Duggan et al	82 M	USA	Sym	Yes	Severe	Early apr	RT PCR	No	Yes	Asym	10 days post discharge	RT PCR	Discharged	
25	Ye-min et al	49 M	China	Sym	NM	mild	22 Jan	RT PCR	NM	Yes	Asym	3 days after discharge	Sputum positive PCR - ve	Discharged	
26	To et al	33M	Hong kong	Sym	No Co-morbi	Mild	29 Mar	RT PCR	NM	Yes	Asymptomatic	123 days after	RT PCR	Discharged	

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

					dity							disc harg e		
27	Tillet et al	25M	USA	Sym	No	Mild	18 Apr	RT PCR	Yes	Yes	Yes	10 days after last negative test	RT PCR	Disc harged
28	Elslande et al	51F	Belgium	Sym	Asthma	moderate	Mar 20	RT PCR	Yes (second time)	No	Yes	10 weeks after home quarantine	RT PCR	Not Hosp
29	Prado-Vivar B et al	46M	Ecuador	Sym	NM	Mild	May 12	RT PCR	Yes	Yes	Yes	6 weeks after being negative	RT PCR	Not hosp
30	Vivek gupta et al	25M 28F	India	Asym	No No	Asym	05 May 17 May	RT PCR RT PCR	NM	Yes	No	100 days after tested negative 101 days	RT PCR	Not Hosp